This study assessed the use, attitudes, and obstacles regarding long-acting injectable (LAI) antipsychotic medications among U.S. psychiatric clinicians treating schizophrenia. Surveying 2330 clinicians with 379 responses, the study found that while clinicians are confident in initiating treatment, they are less sure about transitioning to and administering LAI therapies. Factors like patient nonadherence and the inconvenience of frequent treatments significantly influence their readiness to recommend LAI medications.

The survey highlighted significant educational gaps concerning the advantages and administration of LAI antipsychotics, which are crucial for preventing relapses and reducing hospitalizations. Despite the potential benefits and updated guidelines promoting LAIs based on patient preference, these medications are underutilized due to enduring negative views and practical challenges like needle phobia and storage concerns. Enhancing clinician knowledge and dispelling myths about LAIs could lead to more effective patient discussions and improved treatment outcomes in schizophrenia care.

Reference: Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. Neuropsychiatr Dis Treat. 2022 Jan 26;18:111-123. doi: 10.2147/NDT.S326299. PMID: 35115779; PMCID: PMC8801366.